Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast

J Clin Pharmacol. 2007 May;47(5):660-6. doi: 10.1177/0091270006297920. Epub 2007 Mar 20.

Authors

Nassr Nassr¹, Gezim Lahu, Andreas Hünnemeyer, Oliver von Richter, Dietrich Knoerzer, Felix Reutter, Karl Zech, Robert Hermann

Affiliation

¹ Department of Exploratory Medicine, ALTANA Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz, Germany.

PMID: 17374735
DOI: 10.1177/0091270006297920

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors
Adult
Aluminum Hydroxide / adverse effects
Aluminum Hydroxide / pharmacology*
Aminopyridines / blood
Aminopyridines / pharmacokinetics*
Antacids / adverse effects
Antacids / pharmacology*
Benzamides / blood
Benzamides / pharmacokinetics*
Cross-Over Studies
Cyclic Nucleotide Phosphodiesterases, Type 4
Cyclopropanes / blood
Cyclopropanes / pharmacokinetics
Drug Interactions
Female
Humans
Magnesium Hydroxide / adverse effects
Magnesium Hydroxide / pharmacology*
Male
Middle Aged
Phosphodiesterase Inhibitors / adverse effects
Phosphodiesterase Inhibitors / blood
Phosphodiesterase Inhibitors / pharmacokinetics*

Substances

Aminopyridines
Antacids
Benzamides
Cyclopropanes
Phosphodiesterase Inhibitors
Roflumilast
Aluminum Hydroxide
3',5'-Cyclic-AMP Phosphodiesterases
Cyclic Nucleotide Phosphodiesterases, Type 4
roflumilast N-oxide
Magnesium Hydroxide